Rebhun J, Shin CM, Siddiqui UD, Villa E. Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review. World J Gastrointest Endosc 2023; 15(3): 177-190 [PMID: 37034966 DOI: 10.4253/wjge.v15.i3.177]
Corresponding Author of This Article
Jeffrey Rebhun, MD, Academic Fellow, Department of Gastroenterology, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States. jeffrebhun@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Mar 16, 2023; 15(3): 177-190 Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.177
Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review
Jeffrey Rebhun, Claire M Shin, Uzma D Siddiqui, Edward Villa
Jeffrey Rebhun, Department of Gastroenterology, Oregon Health and Sciences University, Portland, OR 97239, United States
Claire M Shin, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, United States
Uzma D Siddiqui, Center for Endoscopic Research and Therapeutics, University of Chicago, University of Chicago Medicine, Chicago, IL 60637, United States
Edward Villa, Department of Gastroenterology and Hepatology, Northshore University Health System, Evanston, IL 60201, United States
Author contributions: Villa E contributed to conception and design; Rebhun J and Villa E contributed to analysis and interpretation of the data; Rebhun J, Shin CM, Villa E contributed to drafting of the article; Siddiqui UD and Villa E contributed to critical revision of the article for important intellectual content; Rebhun J, Shin CM, Siddiqui UD, Villa E contributed to final approval of the article.
Conflict-of-interest statement: Uzma Siddiqui has served as a speaker/consultant for Boston Scientific, Medtronic, and Olympus. Edward Villa has served as a consultant/speaker for ConMed as well as a speaker for Ovesco.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jeffrey Rebhun, MD, Academic Fellow, Department of Gastroenterology, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States. jeffrebhun@gmail.com
Received: November 3, 2022 Peer-review started: November 3, 2022 First decision: December 11, 2022 Revised: January 12, 2023 Accepted: March 1, 2023 Article in press: March 1, 2023 Published online: March 16, 2023 Processing time: 132 Days and 9.9 Hours
ARTICLE HIGHLIGHTS
Research background
Further prospective studies comparing all therapeutic modalities are needed to best understand their role in the treatment of unresectable cholangiocarcinoma.
Research motivation
Endoscopic radiofrequency ablation with biliary stenting is a promising palliative therapeutic option in patients presenting with unresectable cholangiocarcinoma.
Research objectives
Endoscopic radiofrequency ablation when used in conjunction with biliary stenting showed improved survival benefit when compared to alternative palliative therapies.
Research methods
This is a comprehensive literature review of studies evaluating survival benefit and other clinical outcomes as it relates to the proposed therapeutic interventions.
Research results
To better understand, qualify, and quantify the survival outcomes of endoscopic radiofrequency ablation, percutaneous radiofrequency ablation, and photodynamic therapy in the treatment of unresectable cholangiocarcinoma as it compares to conventional therapy alone.
Research conclusions
Our motivation for this study was to better understand alternative approaches to palliative endoscopic intervention for patients with unresectable cholangiocarcinoma.
Research perspectives
There is limited data evaluating the clinical outcomes of endoscopic radiofrequency ablation and photodynamic therapy as interventions for unresectable cholangiocarcinoma.
